Liposomal Anthracycline Chemotherapy in the Treatment of AIDS-Related Kaposi's Sarcoma

ONCOLOGY

Volumn 11, Issue 10 SUPPL. 12, 1997, Pages 21-32

  Northfelt, Donald W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; BLEOMYCIN SULFATE; DAUNORUBICIN; DOXORUBICIN; LIPOSOME; VINCRISTINE SULFATE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALOPECIA; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CARDIOTOXICITY; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG SAFETY; DRUG TISSUE LEVEL; HUMAN; KAPOSI SARCOMA; MICROENCAPSULATION; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; THROMBOCYTOPENIA;

EID: 0030731376     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Friedman-Kein A, Laubenstein L, Marmor M, et al: Kaposi's sarcoma and pneumocystic pneumonia among homosexual men-New York City and California. MMWR 30 305-308, 1981.
2. Hymes KB, Cheung TL, Green JB, et al. Kaposi's sarcoma in homosexual men: A report of 8 cases. Lance: 2:598-600, 1981.
3. Masur H, Michilis MA, Green JB, et al: An outbreak of community-acquired Pneumocystis carinii pneumonia: Initial manifestations of cellular immune dysfunction. N Engl J Med 305:1431-1438, 1981.
4. Northfelt DW: AlDS-related Kaposi's sarcoma: Still a problem, still an opportunity. J Clin Oncol 12:1109-1110, 1994.
5. Beral V, Peterman TA, Berkelman RL, et al: Kaposi's sarcoma among persons with AIDS. A sexually transmitted infection? Lancet 1:123-128, 1990.
6. Peters BS, Beck EJ, Coleman DG, et al. Changing disease patterns in patients with AIDS in a referral centre in the United Kingdom: The changing face of AIDS. Br J Med 302-203-207, 1991.
7. Selik RM, Chu SY, Ward JW: Trends in infectious disease and cancers among persons dying of HIV infection in the United States from 1987 to 1992 Ann Intern Med 23:933-936, 1995.
8. Gill PS, Akil B, Colletti P, et al: Pulmonary Kaposi's sarcoma. Clinical findings and results of therapy. Am J Med 87:57-61, 1989.
9. Kaplan LD, Hopewell PC, Jaffe H, et al: Kaposi's sarcoma involving the lung in patients with acquired immunodeficiency syndrome. J Acquir Immune Defic Synd 1:23-30, 1988
10. Lemp GF, Payne SF, Neal D, et al: Survival trends for patients with AIDS. JAMA 263:402-406, 1990.
11. Moore PS, Chang Y: Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and those without HIV infection. N Engl J Med 332:1181-1185, 1995.
12. Northfelt DW: Treatment of Kaposi's sarcoma: Current guidelines and future perspectives. Drugs 48:569-582, 1994.
13. Gill PS, Rarick M, McCutchan JA, et al: Systemic treatment of AIDS-related Kaposi's sarcoma: Results of a randomized trial Am J Med 90:427-433, 1991.
14. Gabizon A, Chisin R, Amselem S, et al: Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated Adriamycin. Br J Cancer 64:1125-1132, 1991.
15. Presant CA, Blayney D, Proffitt RT, et al: Preliminary report: Imaging of Kaposi's sarcoma and lymphoma in AIDS with indium-111-labeled liposomes. Lancet 335:1307-1309, 1990.
16. Gabizon AA, Barenholz, Y Bialer M: Prolongation of circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-denvatized phosphohpid: Pharmacokinetic studies in rodents and dogs. Pharm Res 10:703-708, 1993.
17. Huang SK, Mahew E, Gilani S: Pharmaco-kinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Cancer Res 52:6774-6781, 1992.
18. Huang SK, Martin FJ, Jay G, et al. Extravasation and transcytosis of liposomes in Kaposi's sarcoma-like dermal lesions of transgenic mice bearing the HIV tat gene. Am J Pathol 143:10-14, 1993.
19. Vaage J, Barbera-Guillem E, Abra R, et al: Tissue distributions and therapeutic effects of intravenous free and liposomal doxorubicin against human prostatic carcinoma xenografts. Cancer 73-1478-1484, 1994.
20. Northfelt DW, Martin FJ, Working P, et al: Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma. J Clin Pharmacol 36:55-63, 1996.
21. Gill PS, Espina BM, Muggia F, et al: Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin J Clin Oncol 13-996-1003, 1995.
22. Northfelt DW: Stealth liposomal doxorubicin (SLD) delivers more doxorubicin (DOX) to AIDS-Kaposi's sarcoma (AIDS-KS) lesions than to normal skin (abstract 5). Proc Amer Soc Clin Oncol 13:51, 1994.
23. Money-Kyrle JF, Bates F, Ready J, et al: Liposomal daunorubicin in advanced Kaposi's sarcoma: A phase II study. Clin Oncol 5:367-371, 1993.
24. Presant CA, Scolaro M, Kennedy P, et al: Liposomal daunorubicin treatment of HIV-associated Kaposi's sarcoma Lancer 341:1242-1243, 1993
25. Hengge UR, Brockmeyer NH, Baumann M, et al: Liposomal doxorubicin in AIDS-related Kaposi's sarcoma. Lancet 342:497, 1993.
26. Simpson JK, Miller RF, Spittle MF: Liposomal doxorubicin for treatment of AIDS-related Kaposi's sarcoma. Clin Oncol 5:372-374, 1993.
27. Bogner JR, Kronawitter U, Rolinski B et al: Liposomal doxorubicin in the treatment of advanced AIDS-related Kaposi sarcoma. J Acquir Immune Defic Synd 7:463-468, 1994.
28. James ND, Coker RJ, Tomlinson D, et al: Liposomal doxorubicin (DOXIL): An effective new treatment for Kaposi's sarcoma in AIDS. Clin Oncol 6:294-296, 1994.
29. Sturzl M, Zeitz C, Eisenburg B, et al: Liposomal doxorubicin in the treatment of AIDS-associated Kaposi's sarcoma: Clinical, histological and cell biological evaluation. Res Virol 145:261-269, 1994.
30. Wagner D, Kern WV, Kern P: Liposomal doxorubicin in AIDS-related Kaposi's sarcoma: Long-term experiences Clin Investig 72:417-423, 1994.
31. Harrison M, Tomlinson D, Stewart S: Liposome-entrapped doxorubicin: An active agent in AIDS-related Kaposi's sarcoma. J Clin Oncol 13:914-920, 1995.
32. Northfelt DW, Dezube BJ, Thommes JA et al: Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy. J Clin Oncol 15:653-659, 1997.
33. Krown SE, Metroka C, Wernz JC: Kaposi's sarcoma in the acquired immunodeficiency syndrome: A proposal for uniform evaluation, response, and staging criteria. J Clin Oncol 7:1201-1207, 1989.
34. Gill P, Rarick M, Bernstein-Singer M, et al: Treatment of advanced Kaposi's sarcoma using a combination of bleomycin and vincristine. Am J Clin Oncol 13:315-319, 1990.
35. Rarick MU, Gill PS, Montgomery T, et al: Treatment of epidemic Kaposi's sarcoma with combination chemotherapy (vincristine and bleomycin) and zidovudine. Ann Oncol 1:147-149, 1990.
36. Fischl MA, Krown SE, O'Boyle KP, et al: Weekly doxorubicin in the treatment of patients with AIDS-related Kaposi's sarcoma. J Acquir Immun Defic Synd 6:259-264, 1993.
37. Gill PS, Wernz J, Scadden DT, et al: Randomized phase III trial of liposomal daunorubiein versus doxorubicin. bleomycin. and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol 14:2353-2364, 1996.
38. Northfelt DW, Dezube BJ, Thommes JA, et al: Randomized comparative trial of DOXIL vs Adriamycin, bleomycin, and vincristine (ABV) in the treatment of severe AIDS-related Kaposi's sarcoma (AIDS-KS) (abstract) 3rd Conference on Retroviruses and Opportunistic Infections 379, 1996.
39. Stewart S, Jablonowski H, Goebel FD, et al: A randomized comparative trial of liposomal doxorubicin vs. bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. J Clin Oncol, 1997 (in press).
40. Madhavan S, Northfelt DW: Lack of vesicant injury following extravasation of liposomal doxorubicin. JNC1 87:1556-1557, 1995.
41. Berry G, Billingham M, Alderman E, et al: Reduced cardiotoxicity of DOXIL (pegylated liposomal doxorubicin) in AIDS Kaposi's sarcoma patients compared to a matched control group of cancer patients given doxorubicin (abstract). Proc Amer Soc Clin Oncol 843, 1996.